KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Leases (2019 - 2025)

Halozyme Therapeutics (HALO) has disclosed Leases for 8 consecutive years, with $37.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Leases rose 10.31% to $37.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.7 million, a 10.31% increase, with the full-year FY2025 number at $37.7 million, up 10.31% from a year prior.
  • Leases was $37.7 million for Q4 2025 at Halozyme Therapeutics, up from $30.8 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $40.5 million in Q4 2022 to a low of $1.6 million in Q1 2022.
  • A 5-year average of $24.4 million and a median of $33.4 million in 2024 define the central range for Leases.
  • Peak YoY movement for Leases: plummeted 49.27% in 2022, then surged 2410.83% in 2023.
  • Halozyme Therapeutics' Leases stood at $2.0 million in 2021, then skyrocketed by 1920.42% to $40.5 million in 2022, then dropped by 8.98% to $36.8 million in 2023, then fell by 7.23% to $34.2 million in 2024, then grew by 10.31% to $37.7 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Leases are $37.7 million (Q4 2025), $30.8 million (Q3 2025), and $31.9 million (Q2 2025).